Ken Griffin Day One Biopharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$12.72 - $16.03 $260,760 - $328,615	-20,500 Reduced 44.37%	25,700 $358,000
Q2 2024 Aug 14, 2024	BUY	$12.03 - $17.69 $310,374 - $456,402	25,800 Added 126.47%	46,200 $636,000
Q1 2024 May 15, 2024	BUY	$13.56 - $17.46 $70,512 - $90,792	5,200 Added 34.21%	20,400 $337,000
Q4 2023 Feb 14, 2024	SELL	$9.68 - $15.37 $2,904 - $4,611	-300 Reduced 1.94%	15,200 $221,000
Q3 2023 Nov 14, 2023	BUY	$11.22 - $14.86 $25,806 - $34,178	2,300 Added 17.42%	15,500 $190,000
Q2 2023 Aug 14, 2023	SELL	$11.74 - $14.47 $8,218 - $10,129	-700 Reduced 5.04%	13,200 $157,000
Q1 2023 May 15, 2023	BUY	$12.75 - $23.41 $103,275 - $189,621	8,100 Added 139.66%	13,900 $185,000
Q4 2022 Feb 14, 2023	SELL	$18.77 - $22.0 $153,914 - $180,400	-8,200 Reduced 58.57%	5,800 $124,000
Q3 2022 Nov 14, 2022	SELL	$16.44 - $26.57 $115,080 - $185,990	-7,000 Reduced 33.33%	14,000 $280,000

178

84M

144K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $945M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.